| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/JIV137 |
| P698 | PubMed publication ID | 25748320 |
| P50 | author | Peter Andersen | Q54029065 |
| Frank Follmann | Q55176180 | ||
| P2093 | author name string | Karin Erneholm | |
| Ida Rosenkrands | |||
| Anja W Olsen | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Chlamydia trachomatis | Q131065 | ||
| vaccine | Q134808 | ||
| membrane protein | Q423042 | ||
| P304 | page(s) | 978-989 | |
| P577 | publication date | 2015-03-06 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein | |
| P478 | volume | 212 |
| Q90028420 | A Recombinant Chlamydia trachomatis MOMP Vaccine Elicits Cross-serogroup Protection in Mice Against Vaginal Shedding and Infertility |
| Q51765225 | A flow cytometry-based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis |
| Q36564785 | A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs |
| Q28391567 | A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge |
| Q91734951 | Anti-chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti-chlamydia IgG is associated with enhanced risk for incident infection |
| Q36028001 | Antibody and Cytokine Responses of Koalas (Phascolarctos cinereus) Vaccinated with Recombinant Chlamydial Major Outer Membrane Protein (MOMP) with Two Different Adjuvants |
| Q57288656 | Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis |
| Q44059377 | B cell presentation of Chlamydia antigen selects out protective CD4γ13 T cells; implications for genital tract tissue resident memory lymphocyte clusters |
| Q30235030 | Chlamydia trachomatis Genital Infections |
| Q37742680 | Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection. |
| Q37622035 | Comparison of Murine Cervicovaginal Infection by Chlamydial Strains: Identification of Extrusions Shed In vivo |
| Q33601324 | Considerations for the rational design of a Chlamydia vaccine |
| Q97545395 | Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus |
| Q36500269 | Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens |
| Q37665012 | Future prospects for new vaccines against sexually transmitted infections |
| Q35952105 | Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis |
| Q38603068 | Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infection |
| Q37345928 | IFNγ is Required for Optimal Antibody-Mediated Immunity against Genital Chlamydia Infection |
| Q90575906 | Identification of immunogenic outer membrane proteins and evaluation of their protective efficacy against Stenotrophomonas maltophilia |
| Q36027948 | Immunohistochemical Analysis of Scarring Trachoma Indicates Infiltration by Natural Killer and Undefined CD45 Negative Cells |
| Q88983828 | In silico prediction of T- and B-cell epitopes in PmpD: First step towards to the design of a Chlamydia trachomatis vaccine |
| Q54211947 | Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). |
| Q37838344 | Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia |
| Q35821088 | Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies |
| Q36373913 | Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis |
| Q27323271 | Intravaginal Chlamydia trachomatis Challenge Infection Elicits TH1 and TH17 Immune Responses in Mice That Promote Pathogen Clearance and Genital Tract Damage |
| Q33632705 | Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization |
| Q44059220 | National Institute of Allergy and Infectious Diseases workshop report: "Chlamydia vaccines: The way forward". |
| Q93015476 | Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge |
| Q94923882 | Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold |
| Q37835358 | Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen |
| Q89969392 | Protection of outbred mice against a vaginal challenge by a Chlamydia trachomatis serovar E recombinant major outer membrane protein vaccine is dependent on phosphate substitution in the adjuvant |
| Q47194154 | Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis |
| Q37479083 | Quantitative Protein Profiling of Chlamydia trachomatis Growth Forms Reveals Defense Strategies Against Tryptophan Starvation |
| Q37140167 | Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice |
| Q92645127 | Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial |
| Q33694896 | Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract |
| Q37835105 | Status of vaccine research and development of vaccines for Chlamydia trachomatis infection |
| Q47237292 | Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens. |
| Q37837221 | Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis |
| Q37834166 | Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses. |
| Q37834854 | The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge |
| Q91285152 | Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming |
| Q49923334 | Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein (MOMP)-based Fusion Antigen CTH522 into Protein Nanoparticles |
| Q37834874 | Update on Chlamydia trachomatis Vaccinology |
Search more.